EXACT SCIENCES CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.54 USD | -0.43% |
|
+1.59% | -16.84% |
Summary: Exact Sciences Corporation
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Highlights: Exact Sciences Corporation
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses: Exact Sciences Corporation
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's enterprise value to sales, at 4.82 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings Chart: Exact Sciences Corporation
Source: Surperformance
ESG chart: Exact Sciences Corporation
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 11.44B | |||||
| 3.31B | |||||
| - | 2.72B | ||||
| - | 1.34B | ||||
| - | 950M | ||||
| - | 770M | ||||
| 689M | |||||
| Average | 3.03B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
A-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EXAS Stock
- Ratings Exact Sciences Corporation